Mark Daniel Benson, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteomics | 11 | 2023 | 3637 | 1.350 |
Why?
|
| Aptamers, Nucleotide | 4 | 2020 | 166 | 1.070 |
Why?
|
| Blood Proteins | 6 | 2020 | 1123 | 0.990 |
Why?
|
| Metabolomics | 5 | 2023 | 1483 | 0.780 |
Why?
|
| SELEX Aptamer Technique | 1 | 2019 | 19 | 0.720 |
Why?
|
| High-Throughput Screening Assays | 3 | 2020 | 945 | 0.520 |
Why?
|
| Peripheral Arterial Disease | 1 | 2022 | 1188 | 0.400 |
Why?
|
| Proteome | 4 | 2022 | 1798 | 0.380 |
Why?
|
| Coronary Artery Disease | 3 | 2022 | 6489 | 0.380 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 15161 | 0.330 |
Why?
|
| Cardiovascular System | 1 | 2016 | 832 | 0.330 |
Why?
|
| Genome-Wide Association Study | 7 | 2023 | 12264 | 0.310 |
Why?
|
| Genetic Variation | 2 | 2020 | 6546 | 0.270 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2021 | 859 | 0.260 |
Why?
|
| Atherosclerosis | 1 | 2021 | 3444 | 0.250 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 4559 | 0.240 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 2136 | 0.240 |
Why?
|
| Chemokine CX3CL1 | 1 | 2021 | 58 | 0.200 |
Why?
|
| Quantitative Trait Loci | 2 | 2019 | 2019 | 0.190 |
Why?
|
| Teaching Rounds | 1 | 2022 | 253 | 0.160 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2017 | 1265 | 0.160 |
Why?
|
| Echocardiography | 2 | 2021 | 5103 | 0.160 |
Why?
|
| Heredity | 1 | 2017 | 154 | 0.150 |
Why?
|
| Proteoglycans | 1 | 2020 | 835 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3256 | 0.140 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 392 | 0.140 |
Why?
|
| Coronary Disease | 2 | 2022 | 6078 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 725 | 0.120 |
Why?
|
| Risk Factors | 8 | 2023 | 72280 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 11732 | 0.120 |
Why?
|
| Adipocytes | 1 | 2019 | 1182 | 0.110 |
Why?
|
| Heart Failure | 3 | 2021 | 10905 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 2204 | 0.100 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 967 | 0.100 |
Why?
|
| Carotid Artery Diseases | 1 | 2018 | 882 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2017 | 1438 | 0.100 |
Why?
|
| Aptamers, Peptide | 2 | 2022 | 28 | 0.100 |
Why?
|
| Humans | 27 | 2023 | 744220 | 0.100 |
Why?
|
| Phenotype | 5 | 2022 | 16365 | 0.100 |
Why?
|
| Databases, Genetic | 1 | 2017 | 1782 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2949 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 15070 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2022 | 6259 | 0.080 |
Why?
|
| Myocardium | 2 | 2017 | 4776 | 0.080 |
Why?
|
| Longitudinal Studies | 5 | 2022 | 13990 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 19907 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 15525 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 4665 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2019 | 3863 | 0.070 |
Why?
|
| Incidence | 5 | 2022 | 20945 | 0.070 |
Why?
|
| Middle Aged | 11 | 2022 | 213367 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2022 | 23337 | 0.070 |
Why?
|
| Kidney | 1 | 2020 | 7183 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2017 | 4399 | 0.060 |
Why?
|
| Heart Transplantation | 1 | 2017 | 3123 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5755 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2022 | 1157 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 4151 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 25043 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2023 | 23404 | 0.050 |
Why?
|
| Male | 12 | 2022 | 350027 | 0.050 |
Why?
|
| Animals | 4 | 2023 | 168788 | 0.050 |
Why?
|
| Cholesterol, LDL | 2 | 2022 | 2355 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9438 | 0.050 |
Why?
|
| Homoarginine | 1 | 2021 | 9 | 0.050 |
Why?
|
| Orotic Acid | 1 | 2021 | 23 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 81178 | 0.050 |
Why?
|
| Spermine | 1 | 2021 | 70 | 0.050 |
Why?
|
| Uridine | 1 | 2021 | 146 | 0.050 |
Why?
|
| Polyamines | 1 | 2021 | 120 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 5034 | 0.050 |
Why?
|
| Dipeptidases | 1 | 2019 | 38 | 0.050 |
Why?
|
| Cystatin C | 1 | 2021 | 250 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2019 | 58 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 17449 | 0.040 |
Why?
|
| Ribonucleotides | 1 | 2019 | 117 | 0.040 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2019 | 88 | 0.040 |
Why?
|
| Norway | 1 | 2020 | 448 | 0.040 |
Why?
|
| Proline | 1 | 2021 | 458 | 0.040 |
Why?
|
| Follistatin | 1 | 2019 | 141 | 0.040 |
Why?
|
| Female | 11 | 2022 | 380197 | 0.040 |
Why?
|
| Aged | 6 | 2022 | 163253 | 0.040 |
Why?
|
| 5'-Nucleotidase | 1 | 2019 | 160 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 434 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 683 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 188 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 2020 | 697 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2021 | 436 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2019 | 563 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2019 | 625 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 12355 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2019 | 493 | 0.040 |
Why?
|
| Lymphokines | 1 | 2019 | 949 | 0.040 |
Why?
|
| Podocytes | 1 | 2020 | 396 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2019 | 608 | 0.030 |
Why?
|
| Metabolome | 1 | 2022 | 895 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 63119 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 890 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2018 | 588 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 11728 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2017 | 249 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2022 | 1167 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2016 | 354 | 0.030 |
Why?
|
| Adult | 7 | 2022 | 214035 | 0.030 |
Why?
|
| Antibodies | 1 | 2022 | 2461 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 1573 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 1224 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 977 | 0.030 |
Why?
|
| Cholesterol | 1 | 2021 | 2911 | 0.030 |
Why?
|
| Collagen | 1 | 2021 | 2689 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2021 | 2131 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2021 | 21752 | 0.020 |
Why?
|
| United States | 3 | 2022 | 69867 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 2915 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 2940 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2022 | 40559 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5096 | 0.020 |
Why?
|
| Risk | 1 | 2021 | 9685 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 4328 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2021 | 5008 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5076 | 0.020 |
Why?
|
| Massachusetts | 1 | 2020 | 8663 | 0.020 |
Why?
|
| Sex Factors | 1 | 2021 | 10396 | 0.020 |
Why?
|
| Acute Disease | 1 | 2017 | 7148 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2018 | 9849 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 6757 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 15999 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 53280 | 0.020 |
Why?
|
| Genotype | 1 | 2018 | 12956 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 21824 | 0.010 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 2337 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14726 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 12742 | 0.010 |
Why?
|
| Hypertension | 1 | 2020 | 8480 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39045 | 0.010 |
Why?
|
| Prognosis | 1 | 2017 | 29050 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 40063 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 57768 | 0.010 |
Why?
|